ResMed shares just hit a new 52-week low. Should I snap some up?

Should be snapping up this medical device company's shares while they're down in the dumps?

| More on:
A woman with a mobile phone in her hand looks sceptical with a puzzled expression on her face with an eyebrow raised and pursed lips.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares have continued their slide on Wednesday.

In morning trade, the sleep treatment company's shares have dropped over 3% to a 52-week low of $23.65.

This means they are now down 35% from their 52-week high.

Why are ResMed shares at a 52-week low?

There are a couple of reasons why ResMed shares are under pressure at present.

The first was an underwhelming FY 2023 results last month which revealed softer than expected margins.

Also weighing on the company's shares have been concerns over the emergence of weight loss drugs such as Ozempic.

Research shows that 70% of obstructive sleep apnoea (OSA) patients are obese. In light of this, Ozempic is seen as potentially a threat to the sleep treatment industry's growth.

Is this a buying opportunity?

The team at Bell Potter remains very positive on the company and sees major upside ahead for ResMed's shares.

For example, earlier this week, the broker kept the company on its favoured list with a buy rating and a $29 price target. This implies a potential upside of almost 23% for investors over the next 12 months.

The OSA market is growing in the high-single digits and RMD is the largest player, ahead of Philips Respironics. RMD is also expanding in the hospital and home care respiratory ventilation market as well as in-house product development and invests 7% of its revenue into R&D.

The market for OSA and chronic obstructive pulmonary disease (COPD) remains under penetrated, and we expect industry volume growth to continue in the 6-8% range for the foreseeable future. In this regard, the competitive dynamics are very much in favour of RMD due to the Philips recall and improving semiconductor availability.

Overall, this could make recent weakness a great buying opportunity for investors looking for long-term investment options.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »